Fiche centre
Swedish Medical Center
Seattle — United States
Essais liés14clinical trials
VilleSeattlelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02545868
Essais cliniques associés
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| 23-PPV | SEP | Phase 3 | NCT02545868 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | COMPLETED |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| CC-97540 | Myasthénie | Phase 1 | NCT06220201 | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | ACTIVE_NOT_RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| Litifilimab | Lupus | Phase 3 | NCT05352919 | EMERALD — An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |
| Histotripsie — HistoSonics Edison System | Cancer | À vérifier | NCT06486454 | Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | Non applicable | NCT05820087 | The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab Test Formulation | SEP | Phase 2 | NCT07074886 | PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | ACTIVE_NOT_RECRUITING |
| Paradise Ultrasound Renal Denervation Treatment | Hypertension | À vérifier | NCT06297291 | US GPS — Global Paradise System US Post Approval Study | RECRUITING |
| BioSTAR Septal Repair Implant System | Migraine | Phase 2 | NCT00283738 | MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant | UNKNOWN |
| Flow Detection System | Migraine | Phase 3 | NCT01773252 | PFO Detection — Right to Left Cardiac Shunt Detection | TERMINATED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| RNS® System | Épilepsie | Phase 4 | NCT00572195 | RNS® System LTT Study | COMPLETED |